Disparities in utilization of oral anticancer agents and related costs in elderly patients with metastatic renal cell carcinoma in the United States.
Wilson L, Spees L, Pritchard J, Greiner M, Scales C, Baggett C, Kaye D, George D, Zhang T, Wheeler S, Dinan M. Disparities in utilization of oral anticancer agents and related costs in elderly patients with metastatic renal cell carcinoma in the United States. Journal Of Clinical Oncology 2020, 38: 106-106. DOI: 10.1200/jco.2020.38.29_suppl.106.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsRenal cell carcinomaPatient characteristicsCell carcinomaManagement of mRCCSEER-Medicare patientsMultivariable-adjusted modelsMajority of patientsPatient-level characteristicsAnticancer agentsMedicare Part D benefitPart D benefitSurvival persistCertain comorbiditiesElderly patientsMultivariable adjustmentMarried patientsMetastatic diagnosisRace/ethnicity categoriesAdvanced ageInclusion criteriaHispanic ethnicityPatientsPocket spendingRedefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma
Hsiang WR, Kenney PA, Leapman MS. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma. Current Oncology Reports 2020, 22: 35. PMID: 32170461, DOI: 10.1007/s11912-020-0895-y.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaSystemic therapyRenal cell carcinomaCytoreductive nephrectomySurgical therapyCell carcinomaManagement of mRCCPoor-risk metastatic renal cell carcinomaInitial systemic therapyReviewThe treatment landscapeTargeted therapy eraUpfront cytoreductive nephrectomyViable treatment approachSequence of surgeryTherapy eraTreatment landscapeUnselected patientsSurgical managementSummaryRecent evidenceRecent FindingsOneTreatment approachesNephrectomyTherapyOptimal rolePatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply